AKBA vs MSFT: Which Stock is Better?

Side-by-side comparison of Akebia Therapeutics Inc and Microsoft Corp in 2026

Comparison Updated:

AKBA

Akebia Therapeutics Inc

$1.55

MSFT

Microsoft Corp

$418.00

Key Metrics Comparison

MetricAKBAMSFTWinner
Market Cap$417.89MN/AAKBA
P/E RatioN/A24.57MSFT
EPS (TTM)$N/A$16.00MSFT
Revenue Growth0.2%0.2%AKBA
Gross Margin82.9%68.6%AKBA

Analyze AKBA

Full quant analysis

Analyze MSFT

Full quant analysis

Analyze Each Stock

Frequently Asked Questions

Is AKBA or MSFT a better investment?

Comparing AKBA and MSFT: Akebia Therapeutics Inc has a market cap of $417.89M while Microsoft Corp has N/A. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.

What is the difference between AKBA and MSFT?

AKBA (Akebia Therapeutics Inc) and MSFT (Microsoft Corp) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.

Which stock has better value: AKBA or MSFT?

Based on P/E ratios, compare detailed valuation metrics on our dashboard.

Which is growing faster: AKBA or MSFT?

AKBA has higher revenue growth at 0.2% vs 0.2% for MSFT.

Which company is more profitable: AKBA or MSFT?

Akebia Therapeutics Inc (AKBA) has higher gross margins at 82.9% compared to 68.6% for MSFT.

Which is the larger company: AKBA or MSFT?

Akebia Therapeutics Inc (AKBA) is larger with a market cap of $417.89M compared to N/A for MSFT.

Should I buy AKBA or MSFT in 2026?

Both AKBA and MSFT have investment merit. AKBA trades at $1.55 while MSFT trades at $418.00. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.

What are the key differences between AKBA and MSFT stock?

Key differences: Market Cap ($417.89M vs N/A), P/E Ratio (N/A vs 24.6x), Revenue Growth (0.2% vs 0.2%), Gross Margin (82.9% vs 68.6%).

Popular Stock Comparisons